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study were 1) to determine whether there was an associ-
ation between drug costs and medical costs for type 1 dia-
betes patients and, 2) to develop a regression model that
predicts medical costs from drug costs. METHODS: The
records of 315 patients enrolled in a large mid-western
health care plan were reviewed for a 1-year period. The
drug costs included insulin costs and oral diabetes drug
costs. The medical costs included all paid services for
primary and secondary diagnosis of type 1 diabetes iden-
tiﬁed by ICD-9-CM codes. The data were analyzed using
SPSS 10.0. The association between drug and medical
costs was determined using Pearson correlation. The 
signiﬁcance level was set at the 95% conﬁdence interval.
Linear regression analysis was conducted to predict
medical costs from drug costs. The dependent variable
was the logarithm of medical costs. The independent 
variables were drug costs, length of service, additional
therapy, age and gender. RESULTS: There was a statisti-
cally signiﬁcant inverse correlation between drug costs
and medical costs (r = -0.229, CI: -0.33 - -0.13). In 
the regression model the following independent variables
were determined to be predictors of medical costs: drug
costs (b = 0.00, CI: -0.003 - -0.002), additional therapy
(b = -0.362, CI: -0.51 - -0.21) and length of service 
(b = 0.002, CI: 0.001 - 0.002). Age and gender were not
found to be signiﬁcant predictors of medical costs. 
CONCLUSIONS: The inverse correlation implies that if
type 1 diabetes is managed appropriately with drugs, 
the medical costs may be reduced. This may reduce the
overall health care expenditures. The regression model
also showed that as drug costs increased medical costs
decreased. The regression model can be used to predict
the future medical costs if the drug costs are known.
DIABETES—Economic Outcomes
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Cost of illness estimates for chronic diseases can be under-
estimated if only costs related to diagnosis and treatment
of that disease are measured. This underestimation results
from overlooking costs associated with secondary conse-
quences of the disease such as complications and co-
morbid conditions associated with the disease.
OBJECTIVE: Two methods for estimating medical care
costs of diabetes were compared: an “attributable”
method” and a “case-control” method. METHODS: The
study population was all diabetic patients in the 1999
Medical Expenditure Panel Survey, a nationally represen-
tative series of probability surveys on the use and cost of
medical care in the United States. “Attributable” costs
were estimated by summing costs speciﬁcally associated
with diabetes. “Case-control” costs were estimated by
subtracting costs between diabetic cases and non-diabetic
controls which were matched on age, gender, race, and
number of comorbid conditions not related to diabetes.
Costs were summarized for pharmacy, hospital inpatient,
outpatient, and emergency room care and reported in
1999 dollars. RESULTS: The total cost of illness was
$3046 per patient using case-control method compared
to $1151 per patient using the attributable method. The
case-control method found costs to be higher for all cat-
egories of care, with the largest being hospital inpatient
costs. Cost differences were statistically signiﬁcant for 
all categories except for emergency room care. CON-
CLUSIONS: Diabetic “attributed” costs accounted for
only 39% of the total difference in health care costs
between diabetics and matched controls. Patients with
diabetes use more medical services than controls, but a
large portion of this care is not speciﬁcally attributed to
diabetes.
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OBJECTIVES: Few studies have compared the short-term
costs to achieve recommended glycemic goals in Type-2
diabetes. We developed a decision analysis to project costs
of treating patients to glycemic goals from a managed
care perspective and evaluated feasibility of summarizing
this model in an aggregate linear regression (LR) form.
METHODS: A literature-based decision model simulated
the 3-year treatment costs (medical, pharmacy, adverse
events) to achieve an HbA1c < 7% for three cohorts of
patients newly diagnosed with Type-2 diabetes and failing
lifestyle changes. Each cohort was assigned to a different
ﬁrst-line therapy: glipizide GITS, generic metformin, or
rosiglitazone. Add-on treatments occurred as necessary to
achieve glycemic control. To summarize the model in a
LR form, we ﬁrst conducted Monte Carlo simulations
(MCS) of the model for each therapy. The costs (depen-
dent variables) estimated via 1000 MCS runs were then
summarized through OLS regressions, using the most sen-
sitive and/or relevant variables from the decision model
as predictors. We then compared the results generated via
each method. RESULTS: The projected cost differences
between agents with the decision analysis and the aggre-
gate LR form were identical: -$558 (glipizide GITS vs.
metformin), -$1557 (glipizide GITS vs. rosiglitazone),
and -$998 (metformin vs. rosiglitazone). The R2 of 
the LR ranged between .49 and .53. Both methods led 
to identical conclusions regarding which agent was
least/most expensive in >97% of cases. The accordance
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between projected costs across methods was statistically
signiﬁcant (Kappa > 0.80, p < 0.001) in each head-to-
head comparison, conﬁrming the feasibility of using the
LR to approximate the results of the decision analysis.
CONCLUSIONS: Both methods demonstrate that glip-
izide GITS is the least expensive ﬁrst-line therapy for
newly diagnosed Type-2 diabetes patients, followed by
metformin and rosiglitazone. The LR can be used as a
quick and easy tool for use in approximation of the more
comprehensive decision tree.
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OBJECTIVE: The goal of this study was to compare
resource utilization for two insulin delivery devices:
InnoLet® and vial/syringe. METHODS: Diabetic patients
requiring assistance with insulin injections (vision and/
or motor impairments) were followed over two 6-week
periods in a randomized crossover study to estimate the
resource utilization associated with different insulin deliv-
ery systems: the InnoLet® insulin doser or the vial and
syringe. A total of 79 patients were enrolled in the study.
Resource utilization was measured as the number of visits
per day which the nurse/caregivers needed to have with
the patient in order to assist (if required) with an injec-
tion, times the costs for such a visit ($80/hour; minimum
visit 1 hour based on local visiting nursing rate) plus the
daily cost for insulin. RESULTS: The mean age of patients
was 68.2 ± 8.6 years, with a mean A1c level of 7.5 ± 1.4
at baseline. Patients were previously treated with
vial/syringe and required assistance with making injec-
tions. Reported major hypoglycemic events occurred as
frequently with both treatments. The mean daily costs for
home visits associated with the injections were $99 and
$179 for the InnoLet and vials/syringe patients, respec-
tively (p < 0.001). Fifty-three percent of the patients
became independent of nursing/caregiver assistance for
the injections when using InnoLet®. Furthermore, the
mean time spent by nurses or caregivers for assisting in
injection preparation was lower for patients using the
InnoLet doser than for the vial and syringe. CONCLU-
SIONS: Patients using the InnoLet® doser required sig-
niﬁcantly fewer visits from nurses/caregivers, resulting in
less resource utilization, and use of InnoLet® fostered
independence in patients who had difﬁculty with self-
injection using vial and syringe.
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Becaplermin (Regranex®), a recombinant human
platelet-derived growth factor, and graftskin (Apligraf®),
a bilayered tissue-engineered human skin equivalent,
promote the local wound healing process and therefore
reduce the time to complete healing and rate of amputa-
tion of lower extremity in diabetic foot ulcer patients.
However, very limited information is available for the rel-
ative cost-effectiveness of these new treatments. OBJEC-
TIVES: To evaluate the cost-effectiveness of graftskin plus
standard foot care and becaplermin plus standard foot
care in comparison to the standard foot care alone from
the societal perspective. METHODS: A decision analysis
model was built for chronic diabetic foot ulcer patients.
Study period was one year. The effectiveness was mea-
sured in quality-adjusted-life years (QALYs). Data for
QALYs, transition probabilities, efﬁcacy, and costs were
taken mostly from the literature. All costs were adjusted
to 2002 US dollars. Sensitivity analyses were performed
on important parameters including costs and efﬁcacy 
of graftskin and becaplermin, and costs of amputation.
RESULTS: In the base case analysis, graftskin was a dom-
inant strategy over becaplermin and standard care. Also,
becaplermin was the dominant strategy over standard
care alone. Compared to the standard care group and the
becaplermin group, the graftskin group had higher
QALYs (difference was 0.03 and 0.06, respectively). In
terms of savings of medical costs, the graftskin group
gained $2202 and $179, compared to the standard care
group and the becaplermin group during the study
period. The results of the sensitivity analysis were con-
sistent with the results of the base case analysis. CON-
CLUSIONS: Although the standard care costs less at the
initial state, patients receiving the standard care only are
more likely to have costly outcomes compared to patients
receiving graftskin or becaplermin, and this translates
into higher expected costs. Also, results indicate that
treating diabetic foot ulcer patients with graftskin was
more cost-effective than treating with becaplermin.
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